Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
7
AXIM Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
0.95%
Day range:
$0.0016 - $0.0019
52-week range:
$0.0013 - $0.0206
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.14x
P/B ratio:
--
Volume:
891.4K
Avg. volume:
1.1M
1-year change:
-90.91%
Market cap:
$545.2K
Revenue:
$39.5K
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingAXIM Biotechnologies has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, AXIM Biotechnologies has an estimated downside of -- from its current price of $0.0018.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.0018.
Fair Value
-
According to the consensus of 0 analysts, AXIM Biotechnologies has -- downside to fair value with a price target of -- per share.
AXIM vs. S&P 500
-
Over the past 5 trading days, AXIM Biotechnologies has underperformed the S&P 500 by -12.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AXIM Biotechnologies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AXIM Biotechnologies has grown year-over-year revenues for 4 quarters straight. In the most recent quarter AXIM Biotechnologies reported revenues of $17.5K.
Earnings Growth
-
AXIM Biotechnologies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AXIM Biotechnologies reported earnings per share of -$0.01.
Enterprise value:
7.1M
EV / Invested capital:
--
Price / LTM sales:
6.14x
EV / EBIT:
--
EV / Revenue:
76.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.37x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-103.02%
Net Income Margin (TTM):
-4452.06%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-3257.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | -- | $26.2K | $92.9K | $9.9K | $17.5K | |
| Gross Profit | -- | -- | -- | $9.9K | $15.7K | |
| Operating Income | -$7.1M | -$3.9M | -$2.3M | -$697.7K | -$569.4K | |
| EBITDA | -$11.1M | -$7.9M | -$2.9M | -$2.8M | -$1.9M | |
| Diluted EPS | -$0.11 | -$0.05 | -$0.02 | -$0.02 | -$0.01 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1M | $411.8K | $173.2K | $97.5K | $20.2K | |
| Total Assets | $11.1M | $10.4M | $4.5M | $4.2M | $3.7M | |
| Current Liabilities | $2.9M | $1.4M | $2.7M | $8.4M | $6.6M | |
| Total Liabilities | $10.1M | $9.3M | $8.3M | $14M | $13.3M | |
| Total Equity | $999.1K | $1M | -$3.7M | -$9.8M | -$9.5M | |
| Total Debt | $5.5M | $5.9M | $5.5M | $5.4M | $6.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.7M | -$1.4M | -$759K | -$643.6K | $553K | |
| Cash From Investing | -$36.5K | -$2.7K | -$2.8K | -- | -- | |
| Cash From Financing | $2.6M | $1.5M | $670.4K | $687.6K | -$643.7K | |
| Free Cash Flow | -$2.8M | -$1.4M | -$761.8K | -$643.6K | $553K | |
AXIM
Sector
Market Cap
$545.2K
$44.6M
Price % of 52-Week High
8.74%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-21.32%
-0.68%
1-Year Price Total Return
-90.91%
-29.09%
Beta (5-Year)
0.987
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.0019
200-day SMA
Sell
Level
$0.0085
Bollinger Bands (100)
Sell
Level
0.0053 - 0.0053
Chaikin Money Flow
Buy
Level
7.9M
20-day SMA
Sell
Level
$0.0022
Relative Strength Index (RSI14)
Sell
Level
41.3495
ADX Line
Neutral
Level
Williams %R
Neutral
Level
-64.2857
50-day SMA
Sell
Level
$0.0032
MACD (12, 26)
Sell
Level
-0.0003
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-43.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-31.4556)
Sell
CA Score
(Annual)
Level (-17.051)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (27.6904)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Stock Forecast FAQ
In the current month, AXIM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXIM average analyst price target in the past 3 months is --.
-
Where Will AXIM Biotechnologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that AXIM Biotechnologies share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About AXIM Biotechnologies?
Analysts are divided on their view about AXIM Biotechnologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AXIM Biotechnologies is a Sell and believe this share price will rise from its current level to --.
-
What Is AXIM Biotechnologies's Price Target?
The price target for AXIM Biotechnologies over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXIM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AXIM Biotechnologies is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AXIM?
You can purchase shares of AXIM Biotechnologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AXIM Biotechnologies shares.
-
What Is The AXIM Biotechnologies Share Price Today?
AXIM Biotechnologies was last trading at $0.0000 per share. This represents the most recent stock quote for AXIM Biotechnologies. Yesterday, AXIM Biotechnologies closed at $0.0018 per share.
-
How To Buy AXIM Biotechnologies Stock Online?
In order to purchase AXIM Biotechnologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
